Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics and its executives violated securities laws following the company's announcement to stop developing its sickle cell drug pociredir. The FDA's concerns about cancer risks linked to the drug's target led Fulcrum to halt development, causing a sharp stock price drop. The investigation aims to determine if investors can recover losses and if Fulcrum complied with legal requirements. Investors who suffered losses are encouraged to contact Johnson Fistel for potential recovery options.
Bank7 Corp., the parent company of Bank7 based in Oklahoma City, announced a quarterly cash dividend of $0.27 per share on its common stock. The dividend will be paid on July 7, 2026, to shareholders of record as of June 19, 2026. Bank7 operates twel...
Paragonix Technologies will present new clinical findings on its liver and kidney preservation systems at the 2026 American Transplant Congress in Boston. The data, from multi-center clinical registries, highlight the benefits of Paragonix's controll...
Scilex Holding Company announced that its board has set June 15, 2026, as the payment date for a previously declared dividend of Semnur Pharmaceuticals common stock to Scilex shareholders. The record date for eligibility is June 1, 2026, and sharehol...
U.S. stock futures showed mixed signals with S&P 500 futures down and Dow Jones up amid political tensions as the House passed a resolution limiting President Trump's military powers. Key stocks like Broadcom and CrowdStrike saw notable moves, with C...
Morgan Stanley predicts Apple's stock could rise significantly after the Worldwide Developers Conference (WWDC) if the company unveils major AI improvements, especially for Siri and Apple Intelligence. The bank highlights Apple's privacy focus and pa...
